Someone needs to tell Michel Vounatsos that he suffers from a terrible case of tin ear syndrome.
At a time when many Americans are increasingly angry over the cost of medicines, the Biogen chief executive last June slapped a $56,000 price tag on its newly approved Alzheimer’s treatment.
Ever since, nothing but scandal has enveloped him and the company he runs. Moreover, he has further harmed an industry that often struggles — sometimes, for good reason — to convince the public it is on the side of the angels.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect